JP2014074724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014074724A5 JP2014074724A5 JP2014006601A JP2014006601A JP2014074724A5 JP 2014074724 A5 JP2014074724 A5 JP 2014074724A5 JP 2014006601 A JP2014006601 A JP 2014006601A JP 2014006601 A JP2014006601 A JP 2014006601A JP 2014074724 A5 JP2014074724 A5 JP 2014074724A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- amount
- biological sample
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (18)
- Her−2のレベルを、がんを有する被験体がHer−2作用剤による治療に応答する可能性があるかどうかの、疾患の時間経過の、そして/または前記被験体のがんの時間経過における重要事象の可能性の指標とする方法であって、前記方法は、
前記被験体のがん由来の生物学的試料におけるHer−2の発現を測定する工程
を含み、ここで、
前記生物学的試料が、低レベルのHer−2、中程度に高レベルのHer−2、または極めて高レベルのHer−2を有するかが決定され、ここで、
前記低レベルは、Her−2の量が第1のHer−2閾値レベル以下であることを含み、
前記中程度に高レベルは、前記第1のHer−2閾値レベルよりも高く、第2のHer−2閾値レベル未満であるHer−2の量を含み、そして、
前記極めて高レベルは、前記第2の閾値レベル以上のHer−2の量を含み、ここで、前記第2の閾値レベルは、前記第1の閾値レベルより高く;
前記生物学的試料において測定されたHer−2の前記量は、前記被験体がHer−2作用剤による治療に応答する可能性、前記疾患の時間経過、および/または前記被験体のがんの時間経過における重要事象の可能性のうちの少なくとも一つと相関付けられ;そして
前記生物学的試料における中程度に高レベルのHer−2は、Her−2の前記量が低いかまたは極めて高い場合と比較して、前記被験体が、Her−2作用剤による治療に応答する可能性がより高く、長い疾患の時間経過を有する可能性がより高く、そして/または重要事象を有する可能性がより低いことの指標となる、方法。 - 前記方法が、
前記生物学的試料におけるHer−3の発現を測定する工程をさらに含み、ここで、
前記生物学的試料における前記Her−3の量が低いかまたは高いかが決定され、ここで、低いレベルは、第1の閾値レベル未満の前記Her−3の量を含み、そして高いレベルは、第1の閾値レベル以上の前記Her−3の量を含み;
前記生物学的試料において測定された前記Her−2およびHer−3の前記量は、前記被験体がHer−2作用剤による治療に応答する相対的な可能性、前記疾患の時間経過、および/または前記被験体のがんの時間経過における重要事象の可能性のうちの少なくとも一つと相関付けられ、
中程度に高レベルのHer−2、および低い量のHer−3は、前記被験体が、Her−2作用剤による治療に応答する可能性がより高く、長い疾患の時間経過を有する可能性がより高く、そして/または重要事象を有する可能性がより低いことの指標となる、請求項1に記載の方法。 - 前記被験体のがんが、乳がんを含む、請求項1または2のいずれか一項に記載の方法。
- 前記がんが、Her2陽性がんを含む、請求項1〜3のいずれか一項に記載の方法。
- Her−2および/またはHer−3の前記量が、
前記生物学的試料を、Her−2またはHer−3に特異的な結合化合物、および切断誘導部分を有する切断プローブと接触させる工程であって、各結合化合物は切断可能な結合によって前記結合化合物に結合した分子タグを含む、工程、ならびに、
Her−2および/またはHer−3に特異的な前記結合化合物に対応する前記分子タグが放出されるかどうかを検出する工程
により測定される、請求項1〜4のいずれか一項に記載の方法。 - 前記Her−2発現が、全Her−2、Her−2ホモ二量体、Her−2ヘテロ二量体を含む、請求項1〜5のいずれか一項に記載の方法。
- 前記Her−3発現が、Her−3、Her−3ホモ二量体、またはHer−3/Her−2ヘテロ二量体を含む、請求項2〜6のいずれか一項に記載の方法。
- 前記被験体のがんが、癌腫(carcinoma)、リンパ腫、芽腫、肉腫、または白血病である、請求項1〜7のいずれか一項に記載の方法。
- 前記被験体のがんが、扁平上皮がん、肺がん、消化器がん、膵臓がん、神経膠芽腫、子宮頚がん、卵巣がん、肝がん(liver cancer)、膀胱がん、肝がん(hepatoma)、乳がん、結腸がん、結腸直腸がん、子宮内膜癌、唾液腺癌、腎臓がん、前立腺がん、外陰がん、甲状腺がん、肝癌(hepatic carcinoma)、および/または頭頚部がんを含む、請求項1〜8のいずれか一項に記載の方法。
- 前記被験体のがんが、転移性がんまたは原発性がんを含む、請求項1〜9のいずれか一項に記載の方法。
- 前記応答する可能性が、全生存率に関して、無増悪期間に関して、かつ/またはRECISTもしくは他の効果判定基準を用いて測定される、請求項1〜10のいずれか一項に記載の方法。
- 前記Her−2作用剤が、トラスツズマブ、ラパチニブ、AEE−788、または4D5のうちの少なくとも一つを含む、請求項1〜11のいずれか一項に記載の方法。
- 前記Her−2作用剤が、トラスツズマブを含む、請求項1〜12のいずれか一項に記載の方法。
- 前記重要事象が、前記がんに関する診断と、初回の診断、前記がんの1つの病期からより進行した病期への増悪、転移性疾患への増悪、再発、手術、または死亡のうちの少なくとも1つとの間の期間の短縮である、請求項1〜13のいずれか一項に記載の方法。
- 前記生物学的試料が、ホルマリン固定されたパラフィン包埋(FFPE)試料を含む、請求項1〜14のいずれか一項に記載の方法。
- Her−2発現および/もしくはHer−3発現の量が、VERATAG(登録商標)アッセイ、FRETアッセイ、BRETアッセイ、ならびに/または生体分子補完および近接アッセイを用いて測定される、請求項1〜15のいずれか一項に記載の方法。
- Her−2発現および/またはHer−3発現の前記量が、試料におけるタンパク質間相互作用の量を測定および/または定量化することが可能なアッセイを用いて測定される、請求項1〜16のいずれか一項に記載の方法。
- 前記Her−3発現が、Her−3/Her−2ヘテロ二量体を含む、請求項2〜17のいずれか一項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14502909P | 2009-01-15 | 2009-01-15 | |
US61/145,029 | 2009-01-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011546408A Division JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Her−2発現の測定による患者の反応を判定する方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014074724A JP2014074724A (ja) | 2014-04-24 |
JP2014074724A5 true JP2014074724A5 (ja) | 2014-08-28 |
JP5615986B2 JP5615986B2 (ja) | 2014-10-29 |
Family
ID=42340111
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011546408A Withdrawn JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Her−2発現の測定による患者の反応を判定する方法 |
JP2014006601A Active JP5615986B2 (ja) | 2009-01-15 | 2014-01-17 | Her−2発現の測定による患者の反応を判定する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011546408A Withdrawn JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Her−2発現の測定による患者の反応を判定する方法 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20100233732A1 (ja) |
EP (1) | EP2387717B1 (ja) |
JP (2) | JP2012515353A (ja) |
KR (1) | KR20110120890A (ja) |
CN (1) | CN102439452B (ja) |
AU (1) | AU2010204576A1 (ja) |
BR (1) | BRPI1007048A2 (ja) |
CA (1) | CA2749817A1 (ja) |
ES (1) | ES2526519T3 (ja) |
IL (1) | IL214067A0 (ja) |
SG (1) | SG172984A1 (ja) |
WO (1) | WO2010083463A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
US8357277B2 (en) | 2007-11-27 | 2013-01-22 | Laboratory Corp. of America Holdings | Enhanced method for detecting and/or quantifying an analyte in a sample |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
CA2764386C (en) * | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
SG10201408392PA (en) | 2009-01-15 | 2015-01-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
ES2925983T3 (es) | 2010-07-27 | 2022-10-20 | Genomic Health Inc | Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
WO2012159115A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
FR2993668B1 (fr) * | 2012-07-17 | 2015-07-03 | Cisbio Bioassays | Methode theranostique basee sur la detection de dimeres her2-her2 |
WO2014165855A1 (en) | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
JP6909156B2 (ja) * | 2014-11-25 | 2021-07-28 | ヴェンタナ メディカル システムズ, インク. | 化学ライゲーション及びハプテン移行を用いた近接アッセイ |
US20180209981A1 (en) * | 2015-07-23 | 2018-07-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
CA3016914C (en) | 2016-03-15 | 2019-08-27 | Laboratory Corporation Of America Holdings | Methods of assessing protein interactions between cells |
JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
JP6922444B2 (ja) * | 2016-11-11 | 2021-08-18 | コニカミノルタ株式会社 | 蛍光ナノ粒子を用いた、病理学的完全奏効(pCR)の予測を支援するための検査支援方法 |
EP3807640A4 (en) * | 2018-06-14 | 2022-04-13 | Memorial Sloan Kettering Cancer Center | METHOD OF PREDICTING THE SENSITIVITY OF LUNG CANCER PATIENTS TO HER2 TARGETING THERAPY |
KR102317202B1 (ko) * | 2018-10-19 | 2021-10-25 | 주식회사 프로티나 | 유방암 재발 예측 방법 |
KR20230134232A (ko) | 2022-03-14 | 2023-09-21 | 부산대학교 산학협력단 | 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ282849A (en) * | 1994-03-29 | 1998-05-27 | Celltech Therapeutics Ltd | Antibodies against e-selectin; whole antibodies of neutral isotype, being variants of natural antibodies altered in the fc region |
SE9601676D0 (sv) * | 1996-04-30 | 1996-04-30 | Ulf Landegren | Improved probing of specific mucleic acids |
US6335479B1 (en) * | 1998-10-13 | 2002-01-01 | Dai Nippon Printing Co., Ltd. | Protective sheet for solar battery module, method of fabricating the same and solar battery module |
US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
US6627400B1 (en) * | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
US6682887B1 (en) * | 1999-04-30 | 2004-01-27 | Aclara Biosciences, Inc. | Detection using degradation of a tagged sequence |
US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
US20040248150A1 (en) * | 1999-04-02 | 2004-12-09 | Sharat Singh | Methods employing oligonucleotide-binding e-tag probes |
US20030092012A1 (en) * | 2001-11-09 | 2003-05-15 | Ahmed Chenna | Methods for detecting a plurality of analytes by chromatography |
US6649351B2 (en) * | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
US7001725B2 (en) * | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
US6673550B2 (en) * | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
US7037654B2 (en) * | 1999-04-30 | 2006-05-02 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
US20030235832A1 (en) * | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
US6162593A (en) * | 1999-10-26 | 2000-12-19 | Wyatt; Marion F. | Diisopropylbenzene containing solvent and method of developing flexographic printing plates |
DE19963849A1 (de) * | 1999-12-30 | 2001-07-12 | Giesecke & Devrient Gmbh | Datenträger mit gedrucktem Sicherheitselement |
US7306904B2 (en) * | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
US6743911B2 (en) * | 2000-03-14 | 2004-06-01 | Shell Oil Company | Process for the carbonylation of pentenenitrile |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
US20040067498A1 (en) * | 2000-04-28 | 2004-04-08 | Ahmed Chenna | Detection of nucleic acid sequences by cleavage and separation of tag-containing structures |
US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
US7255999B2 (en) * | 2001-05-21 | 2007-08-14 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
US20030207300A1 (en) * | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
CA2417355A1 (en) * | 2000-08-08 | 2002-02-14 | Aclara Biosciences, Inc. | Multiplexed enzymatic assays |
EP1236740B1 (de) * | 2001-02-28 | 2012-07-18 | Bio Life Science Forschungs- und Entwicklungsges.m.b.H. | Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind |
US7183388B2 (en) * | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
US7041459B2 (en) * | 2001-05-21 | 2006-05-09 | Monogram Biosciences, Inc. | Analyzing phosphorylated proteins |
US7358052B2 (en) * | 2001-05-26 | 2008-04-15 | Monogram Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
US7446185B2 (en) * | 2001-07-18 | 2008-11-04 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
US20040241688A1 (en) * | 2001-07-19 | 2004-12-02 | Cuneyt Bukusoglu | Human tissue specific drug screening procedure |
GB2378245A (en) * | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
WO2003033741A1 (en) * | 2001-10-16 | 2003-04-24 | Aclara Biosciences, Inc. | Universal e-tag primer and probe compositions and methods |
US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
US6659577B2 (en) * | 2001-12-06 | 2003-12-09 | Hewlett-Packard Development Company, L.P. | Dual flat springs for tool-less slide installation |
US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
JP4488746B2 (ja) * | 2002-02-26 | 2010-06-23 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 抗−ヒトテネイシンモノクローナル抗体 |
KR20040108655A (ko) * | 2002-03-05 | 2004-12-24 | 아클라라 바이오사이언시스 인코퍼레이티드 | 막-결합된 민감제를 사용하는 복합 분석법 |
DK2799555T3 (en) * | 2002-03-13 | 2017-05-22 | Genomic Health Inc | Gene Expression Profiling in Tumor Tissue Biopsies |
WO2003085374A2 (en) * | 2002-04-02 | 2003-10-16 | Aclara Biosciences, Inc. | Multiplexed assays using electrophoretically separated molecular tags |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
US20090111127A1 (en) * | 2002-05-21 | 2009-04-30 | Monogram Biosciences Inc. | Surface Receptor Complexes as Biomarkers |
US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US7402397B2 (en) * | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
US20040175765A1 (en) * | 2002-07-05 | 2004-09-09 | Sharat Singh | Cell-screening assay and composition |
PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
EP1540347B1 (en) * | 2002-07-25 | 2009-09-09 | Aclara BioSciences, Inc. | Detecting receptor oligomerization |
AU2003249050A1 (en) * | 2002-07-26 | 2004-02-16 | Monogram Biosciences, Inc. | Lipophilic electrophoretic probes |
US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
WO2004092353A2 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
US20100291594A1 (en) * | 2003-07-17 | 2010-11-18 | Laboratory Corporation Of America Holdings | ErbB Surface Receptor Complexes as Biomarkers |
US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
JP2007502417A (ja) * | 2003-08-11 | 2007-02-08 | モノグラム バイオサイエンシズ,インコーポレーテッド | 分子複合体の検出および特徴づけ |
US20070059785A1 (en) * | 2003-08-15 | 2007-03-15 | Smithkline Beecham Corporation | Biomarkers in cancer |
US20050106571A1 (en) * | 2003-10-02 | 2005-05-19 | The Regents Of The University Of California | Mammalian T1R3 sweet taste receptors |
EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
CN111925445A (zh) * | 2004-07-09 | 2020-11-13 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
US20080254497A1 (en) * | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
US8338579B2 (en) * | 2004-11-03 | 2012-12-25 | Iris Molecular Diagnostics, Inc. | Homogeneous analyte detection |
US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
US20060212956A1 (en) * | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
US8357277B2 (en) * | 2007-11-27 | 2013-01-22 | Laboratory Corp. of America Holdings | Enhanced method for detecting and/or quantifying an analyte in a sample |
CN101230390A (zh) * | 2007-12-07 | 2008-07-30 | 湖北大学 | 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法 |
EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
CA2764386C (en) * | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
SG10201408392PA (en) * | 2009-01-15 | 2015-01-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
-
2010
- 2010-01-15 CA CA2749817A patent/CA2749817A1/en not_active Abandoned
- 2010-01-15 JP JP2011546408A patent/JP2012515353A/ja not_active Withdrawn
- 2010-01-15 SG SG2011051000A patent/SG172984A1/en unknown
- 2010-01-15 CN CN201080009544.4A patent/CN102439452B/zh not_active Expired - Fee Related
- 2010-01-15 BR BRPI1007048A patent/BRPI1007048A2/pt not_active Application Discontinuation
- 2010-01-15 WO PCT/US2010/021272 patent/WO2010083463A1/en active Application Filing
- 2010-01-15 ES ES10732178.8T patent/ES2526519T3/es active Active
- 2010-01-15 KR KR1020117018898A patent/KR20110120890A/ko not_active Application Discontinuation
- 2010-01-15 EP EP10732178.8A patent/EP2387717B1/en not_active Revoked
- 2010-01-15 US US12/688,766 patent/US20100233732A1/en not_active Abandoned
- 2010-01-15 AU AU2010204576A patent/AU2010204576A1/en not_active Abandoned
-
2011
- 2011-07-13 IL IL214067A patent/IL214067A0/en unknown
-
2014
- 2014-01-17 JP JP2014006601A patent/JP5615986B2/ja active Active
- 2014-07-02 US US14/322,317 patent/US20140370523A1/en not_active Abandoned
-
2016
- 2016-06-15 US US15/183,151 patent/US20170082626A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014074724A5 (ja) | ||
Chua et al. | Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review | |
Shibuya et al. | CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma | |
JP5615986B2 (ja) | Her−2発現の測定による患者の反応を判定する方法 | |
Janmaat et al. | Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients | |
JP2012515353A5 (ja) | ||
Adackapara et al. | Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE 1 is not a useful surrogate for genotyping in colorectal adenocarcinoma | |
US10416162B2 (en) | Her2 diagnostic methods | |
Gao et al. | Clinical implications of variant ALK FISH rearrangement patterns | |
Nuciforo et al. | Quantification of HER family receptors in breast cancer | |
Koutras et al. | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study | |
Funk et al. | High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma | |
Li et al. | Prognostic significance of cytoskeleton‐associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma | |
Gruber et al. | A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry | |
Berezowska et al. | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas | |
Lamberts et al. | Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types | |
JP2016517960A5 (ja) | ||
Riveiro‐Falkenbach et al. | DEK oncogene is overexpressed during melanoma progression | |
Augustin et al. | Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer | |
Ross | Update on HER2 testing for breast and upper gastrointestinal tract cancers | |
US20130216523A1 (en) | Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression | |
Monteiro et al. | Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas | |
Akagi et al. | Visinin‐like protein‐1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients | |
Zhang et al. | Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis | |
JP6626037B2 (ja) | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |